Proof-of-concept trial of efgartigimod in membranous nephropathy
Latest Information Update: 09 Mar 2022
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Membranous glomerulonephritis
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 09 Mar 2022 New trial record
- 03 Mar 2022 According to an argenx media release, Zai Lab expect to launch this trial in 2022.